Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 5807346, 9 pages
http://dx.doi.org/10.1155/2016/5807346
Review Article

Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis

1Department of Neurosurgery, First Clinical Medical College of Lanzhou University, Lanzhou 730000, China
2Evidence-Based Medicine Center of Lanzhou University, Lanzhou 730000, China
3Key Laboratory of Evidence-Based Medicine and Knowledge Translation of Gansu Province, Lanzhou 730000, China
4Department of Neurosurgery, Affiliated Hospital, Medical College of Chinese People’s Armed Police, Tianjin 300162, China

Received 3 July 2015; Accepted 2 December 2015

Academic Editor: Jun Deng

Copyright © 2016 Mao-hua Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Gállego Pérez-Larraya and J. Hildebrand, “Brain metastases,” in Handbook of Clinical Neurology, vol. 121 of Neurologic Aspects of Systemic Disease Part III, chapter 77, pp. 1143–1157, Elsevier, 2014. View at Publisher · View at Google Scholar
  2. D. E. Dawe, J. N. Greenspoon, and P. M. Ellis, “Brain metastases in non-small-cell lung cancer,” Clinical Lung Cancer, vol. 15, no. 4, pp. 249–257, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. C. G. Patil, K. Pricola, J. M. Sarmiento, S. K. Garg, A. Bryant, and K. L. Black, “Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases,” Cochrane Database of Systematic Reviews, vol. 9, Article ID CD006121, 2012. View at Google Scholar · View at Scopus
  4. F. J. Lagerwaard, P. C. Levendag, P. J. C. M. Nowak, W. M. H. Eijkenboom, P. E. J. Hanssens, and P. I. M. Schmitz, “Identification of prognostic factors in patients with brain metastases: a review of 1292 patients,” International Journal of Radiation Oncology, Biology, Physics, vol. 43, no. 4, pp. 795–803, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Franciosi, G. Cocconi, M. Michiara et al., “Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, non small cell lung carcinoma, or malignant melanoma: a prospective study,” Cancer, vol. 85, pp. 1599–1605, 1999. View at Google Scholar
  6. X.-X. Dinglin, Y. Huang, H. Liu, Y.-D. Zeng, X. Hou, and L.-K. Chen, “Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial,” Journal of Neuro-Oncology, vol. 112, no. 3, pp. 461–466, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Cortes, J. Rodriguez, J. M. Aramendia et al., “Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer,” Oncology, vol. 64, no. 1, pp. 28–35, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. P. Kleisbauer, J. C. Guerin, A. Arnaud, R. Poirier, and D. Vesco, “Chemotherapy with high-dose cisplatin in brain metastasis of lung cancers,” Bulletin du Cancer, vol. 77, pp. 661–665, 1990. View at Google Scholar
  9. C. Cotto, J. Berille, P. J. Souquet et al., “A phase II trial of fotemustine and cisplatin in central nervous system metastases from nonsmall cell lung cancer,” European Journal of Cancer, vol. 32, no. 1, pp. 69–71, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Fujita, S. Fukuoka, H. Takabatake, S. Tagaki, and K. Sekine, “Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer,” Oncology, vol. 59, no. 4, pp. 291–295, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Ma, Y. Xu, Q. Deng, and X. Yu, “Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population,” Lung Cancer, vol. 65, no. 2, pp. 198–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Lombardi, A. L. Di Stefano, P. Farina, V. Zagonel, and E. Tabouret, “Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature,” Cancer Treatment Reviews, vol. 40, no. 8, pp. 951–959, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Barlesi, J.-P. Spano, A. B. Cortot, A. F. Carpentier, G. Robinet, and B. Besse, “Systemic treatment of brain metastases from lung cancer,” Cancer/Radiothérapie, vol. 19, no. 1, pp. 43–47, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Liberati, D. G. Altman, J. Tetzlaff et al., “The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration,” British Medical Journal, vol. 339, Article ID b2700, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Tarro, A. Perna, and C. Esposito, “Early diagnosis of lung cancer by detection of tumor liberated protein,” Journal of Cellular Physiology, vol. 203, no. 1, pp. 1–5, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. S. L. Spruance, J. E. Reid, M. Grace, and M. Samore, “Hazard ratio in clinical trials,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 8, pp. 2787–2792, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. J. P. T. Higgins and S. Green, Cochrance Handbook for Systematic Reviews of Interventions Version 5.1.0 [EB/OL], The Cochrane Collaboration, 2011, http://www.cochrane-handbook.org.
  18. J. P. T. Higgins and S. G. Thompson, “Quantifying heterogeneity in a meta analysis,” Statistics in Medicine, vol. 21, no. 11, pp. 1539–1558, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994. View at Publisher · View at Google Scholar · View at Zentralblatt MATH · View at Scopus
  20. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” British Medical Journal, vol. 315, no. 7109, pp. 629–634, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Zhuang, Z. Yuan, J. Wang, L. Zhao, Q. Pang, and P. Wang, “Phase ii study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma,” Drug Design, Development and Therapy, vol. 7, pp. 1179–1186, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. S. M. Lee, C. R. Lewanski, N. Counsell et al., “Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases,” Journal of the National Cancer Institute, vol. 106, no. 7, Article ID dju151, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Fu, X. L. Zhang, Y. Xiao, X. J. Liu, C. Long, and Y. D. Hu, “Evaluafion of gefitlulb plus radiotherapy in non-small-cell lung cancer pafients with brain metastases,” National Medical Journal of China, vol. 92, no. 8, pp. 524–527, 2012. View at Google Scholar
  24. T. A. Wu, D. R. Liu, Z. H. Wang, and Y. Pen, “Effects of gefitinib combined with whole brain radiation on brain metastasis from non-small-cell lung cancer,” Chinese Journal of General Practice, vol. 10, no. 6, pp. 893–895, 2012. View at Google Scholar
  25. D. Zhou, X. Xu, H.-Y. Xie, X.-M. Ma, and Y.-R. Bai, “Therapeutic effects of whole brain radiotherapy with targeted therapy and concomitant chemo-radiotherapy in treatment of non-small-cell lung cancer with brain metastasis,” Journal of Shanghai Jiaotong University, vol. 33, no. 4, pp. 480–484, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. G. A. Pesce, D. Klingbiel, K. Ribi et al., “Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03),” European Journal of Cancer, vol. 48, no. 3, pp. 377–384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Cai, J.-Y. Wang, and H. Liu, “Clinical observation of whole brain radiotherapy concomitant with targeted therapy for brain metastasis in non-small cell lung cancer patients with chemotherapy failure,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 10, pp. 5699–5703, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Y. Kim, C. K. Hong, T. H. Kim et al., “Efficacy of surgical treatment for brain metastasis in patients with non-small cell lung cancer,” Yonsei Medical Journal, vol. 56, no. 1, pp. 103–111, 2015. View at Publisher · View at Google Scholar
  29. M. Preusser, D. Capper, A. Ilhan-Mutlu et al., “Brain metastases: pathobiology and emerging targeted therapies,” Acta Neuropathologica, vol. 123, no. 2, pp. 205–222, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. J. R. Johnson, M. Cohen, R. Sridhara et al., “Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen,” Clinical Cancer Research, vol. 11, no. 18, pp. 6414–6421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Wang, Y. Wang, B. Wang et al., “Primary result of the efficacy and tolerance of gefitinib in advanced non-small cell lung cancer patients with brain metastasis,” Chinese Journal of Lung Cancer, vol. 9, no. 5, pp. 447–451, 2006. View at Google Scholar · View at Scopus
  32. J. W. Welsh, R. Komaki, A. Amini et al., “Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 31, no. 7, pp. 895–902, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Jamal-Hanjani and J. Spicer, “Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain,” Clinical Cancer Research, vol. 18, no. 4, pp. 938–944, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. H.-K. Sun, J.-H. Zheng, and W.-M. Zhang, “Research progress of brain metastasis in non-small cell cancer with different EGFR gene status,” Chinese Journal of Cancer Prevention and Treatment, vol. 21, no. 10, pp. 795–799, 2014. View at Google Scholar · View at Scopus